Sonoma Pharmaceuticals (SNOA) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$21.9M

Revenue (quarter)

$6.4M

Revenue growth (year over year)

+59.55%

Gross profit (trailing twelve months)

$8.5M

Gross margin

38.91%

Net income (trailing twelve months)

−$2.3M

Net income (quarter)

−$330,000.00

Net income growth (year over year)

+73.41%

Net margin

−10.33%

Return on equity

−42.52%

EPS (trailing twelve months)

−$1.22

Book value per share

$1.38

P/E (trailing twelve months)

—

Price to book

0.84

Debt to assets

63.58%

Payout ratio

—

Dividend yield

—

Company profile

Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.

• Is Sonoma Pharmaceuticals (SNOA) profitable?

  No. Sonoma Pharmaceuticals reported a net loss of $2.3M over the trailing twelve months.

• How much revenue does Sonoma Pharmaceuticals (SNOA) make?

  Sonoma Pharmaceuticals generated $21.9M in revenue over the trailing twelve months, up 59.55% year over year.

• How do I buy stock in Sonoma Pharmaceuticals (SNOA)?

  SNOA trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.